Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Jose F. Ponte; Olga Ab; Leanne Lanieri; Jenny Lee; Jennifer Coccia; Laura M. Bartle; Marian Themeles; Yinghui Zhou; Jan Pinkas; Rodrigo Ruiz-Soto

doi:10.1016/j.neo.2016.11.002

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Neoplasia ◽

10.1016/j.neo.2016.11.002 ◽

2016 ◽

Vol 18 (12) ◽

pp. 775-784 ◽

Cited By ~ 29

Author(s):

Jose F. Ponte ◽

Olga Ab ◽

Leanne Lanieri ◽

Jenny Lee ◽

Jennifer Coccia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Standard Of Care ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Cancer Models ◽

Antibody Drug

Download Full-text

Combination Regimens of Mirvetuximab Soravtansine, A Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, With Standard-Of-Care Agents Offer Promise for the Treatment of Ovarian Cancer

Health Care Current Reviews ◽

10.4172/2375-4273.1000195 ◽

2017 ◽

Vol 05 (02) ◽

Author(s):

Todd M Bauer

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Standard Of Care ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Combination Regimens ◽

Antibody Drug

Download Full-text

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Annals of Oncology ◽

10.1093/annonc/mdz250 ◽

2019 ◽

Vol 30 ◽

pp. v403 ◽

Cited By ~ 8

Author(s):

K. Moore ◽

A. Oza ◽

N. Colombo ◽

A. Oaknin ◽

G. Scambia ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Phase Iii ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Phase Iii Study ◽

Antibody Drug

Download Full-text

Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.11.066 ◽

2020 ◽

Vol 156 (3) ◽

pp. e15-e16

Author(s):

Kathleen G. Essel ◽

Lainie P. Martin ◽

David M. O’Malley ◽

Ursula Matulonis ◽

Jason A. Konner ◽

...

Keyword(s):

Ovarian Cancer ◽

Safety Profile ◽

Folate Receptor ◽

Recurrent Ovarian Cancer ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Antibody Drug

Download Full-text

Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer

Annals of Oncology ◽

10.1093/annonc/mdz250.036 ◽

2019 ◽

Vol 30 ◽

pp. v419-v420

Author(s):

D. O'Malley ◽

D. Richardson ◽

I.B. Vergote ◽

L. Gilbert ◽

L.P. Martin ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Initial Results ◽

Antibody Drug

Download Full-text

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.04.085 ◽

2018 ◽

Vol 149 ◽

pp. 38 ◽

Cited By ~ 10

Author(s):

U.A. Matulonis ◽

K.N. Moore ◽

L.P. Martin ◽

I.B. Vergote ◽

C.M. Castro ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.07.017 ◽

2018 ◽

Vol 151 (1) ◽

pp. 46-52 ◽

Cited By ~ 16

Author(s):

Kathleen N. Moore ◽

David M. O'Malley ◽

Ignace Vergote ◽

Lainie P. Martin ◽

Antonio Gonzalez-Martin ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Sensitive ◽

Phase 1B ◽

Antibody Drug

Download Full-text

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5549 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5549-5549

Author(s):

David M. O'Malley ◽

Lainie P. Martin ◽

Lucy Gilbert ◽

Ignace Vergote ◽

Ursula A. Matulonis ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Activity Profile ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Phase 1B ◽

Antibody Drug

Download Full-text

833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.08.972 ◽

2020 ◽

Vol 31 ◽

pp. S626-S627

Author(s):

D.M. O'Malley ◽

D.L. Richardson ◽

I.B. Vergote ◽

L. Gilbert ◽

C. Castro ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Sensitive ◽

Antibody Drug

Download Full-text

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.01.037 ◽

2020 ◽

Vol 157 (2) ◽

pp. 379-385 ◽

Cited By ~ 7

Author(s):

David M. O'Malley ◽

Ursula A. Matulonis ◽

Michael J. Birrer ◽

Cesar M. Castro ◽

Lucy Gilbert ◽

...

Keyword(s):

Ovarian Cancer ◽

Folate Receptor ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Phase Ib ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text

IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5567 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 2

Author(s):

Kathleen N. Moore ◽

Lainie P. Martin ◽

Ursula A. Matulonis ◽

Jason A. Konner ◽

Shelly Marie Seward ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Folate Receptor ◽

Single Agent ◽

Antibody Drug Conjugate ◽

Folate Receptor Alpha ◽

Receptor Alpha ◽

Drug Conjugate ◽

Platinum Resistant ◽

Antibody Drug

Download Full-text